Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human betaA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After establishing that β-globin lentiviral vectors had successfully corrected models of β-thalassemia and sickle cell disease in mice, 17,18 we initiated a human clinical study of ex vivo gene therapy for the β-hemoglobinopathies”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [17]
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“, referred to as the locus control region (LCR), are linked to the globin gen”
BackgroundMalim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 1×
“Here we report how these problems may be overcome by using vectors derived from human immunodeficiency virus 1, a retrovirus that has the ability to regulate packaging of unspliced viral genome”
Hematology of Infancy and Childhood.
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-587_2 · Cited by 892
The Molecular Basis of Blood Diseases.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-950_3 · Cited by 632
Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M., & Torbett, B. E. (1999) · Science · doi:10.1126/science.283.5402.682 · Cited by 624
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“The same outcome prevails in transgenic mice unless genomic elements encompassing DNase I hypersensitive sites (HS) located 60 kilobases (kb) upstream of the human β-globin gen”
BackgroundLooping versus linking: toward a model for long-distance gene activation
Bulger, M., & Groudine, M. (1999) · Genes & Development · doi:10.1101/gad.13.19.2465 · Cited by 484
Raj, S. R., Chen, S. R. W., Sheldon, R. S., Shah, A. N., Kantharia, B. K., Salzer, U., Grimbacher, B., Leung, A. K. C., Kamat, D., Kolovou, G. D., et al. (2009) · Encyclopedia of Molecular Mechanisms of Disease · doi:10.1007/978-3-540-29676-8_1731 · Cited by 475
Cited by
Items 101–200 of 622
Breda, L., Casu, C., Gardenghi, S., Bianchi, N., Cartegni, L., Narla, M., Yazdanbakhsh, K., Musso, M., Manwani, D., Little, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032345 · Cited by 83
Self-citationA Look to Future Directions in Gene Therapy Research for Monogenic Diseases
Porteus, M. H., Connelly, J. P., & Pruett‐Miller, S. M. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020133 · Cited by 87
“May et al. (2000), for example, used such a comparison to demonstrate that a b-globin–expressing lentivirus with longer hypersensitivity regions from the b-globin locus control region was better than a vector with shorter hypersensitivity regions [28].”
MethodGene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
Self-citationDonahue, R. E., & Dunbar, C. E. (2001) · Human Gene Therapy · doi:10.1089/104303401300057289 · Cited by 86
[29] Transduction of a gene expression cassette using advanced generation lentiviral vectors
Palma, M. D., & Naldini, L. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)46074-0 · Cited by 85
Development of an Avian Leukosis-Sarcoma Virus Subgroup A Pseudotyped Lentiviral Vector
Lewis, B. C., Chinnasamy, N., Morgan, R. A., & VARMUS, H. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.9339-9344.2001 · Cited by 84
Brenner, S., & Malech, H. L. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(03)00024-7 · Cited by 84
Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects
Mansilla-Soto, J., Riviere, I., Boulad, F., & Sadelain, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.037 · Cited by 83
Self-citationRecruitment of Transcription Complexes to the β-Globin Gene Locus in Vivo and in Vitro
Vieira, K. F., Levings, P. P., Hill, M. A., Crusselle, V. J., Kang, S.-H. L., Engel, J. D., & Bungert, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408883200 · Cited by 68
Oral ferroportin inhibitor VIT‐2763: First‐in‐human, phase 1 study in healthy volunteers
Richard, F., van Lier, J. J., Roubert, B., Haboubi, T., Göhring, U., & Dürrenberger, F. (2020) · American Journal of Hematology · doi:10.1002/ajh.25670 · Cited by 72
Thalassemia: An Overview of 50 Years of Clinical Research
Sankaran, V. G., & Nathan, D. G. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.08.009 · Cited by 80
Opportunities for the Use of Lentiviral Vectors in Human Gene Therapy
Galimi, F., & Verma, I. M. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-56114-6_13 · Cited by 78
Stem cell–derived erythroid cells mediate long-term systemic protein delivery
Chang, A. H., Stephan, M. T., & Sadelain, M. (2006) · Nature Biotechnology · doi:10.1038/nbt1227 · Cited by 78
“We constructed two self-inactivating lentiviral vectors that encode hFIX under the transcriptional control of the human β-globin promoter, enhancers and locus control regio”
MethodSelf-citationDevelopment of gene therapy for blood disorders
Nienhuis, A. W. (2008) · Blood · doi:10.1182/blood-2007-11-078121 · Cited by 78
Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
Rao, V. K., Kapp, D., & Schroth, M. K. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.12-a.s3 · Cited by 77
Gene therapy for chronic granulomatous disease
Barese, C. N., Goebel, W. S., & Dinauer, M. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.9.1423 · Cited by 71
“Recent studies suggest that vectors derived from lentiviruses will be useful for the correction of genetic blood diseases [75-80].”
BackgroundLentiviral gene transfer into peripheral blood–derived CD34+ NOD/SCID-repopulating cells
Scherr, M., Battmer, K., Blömer, U., Schiedlmeier, B., Ganser, A., Grez, M., & Eder, M. (2002) · Blood · doi:10.1182/blood.v99.2.709 · Cited by 76
Pharmacologically regulated in vivo selection in a large animal
Neff, T., Horn, P. A., Valli, V. E., Gown, A. M., Wardwell, S., Wood, B. L., von Kalle, C., Schmidt, M., Peterson, L. J., Morris, J. C., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0792 · Cited by 76
Boulad, F., Wang, X., Qu, J., Taylor, C., Ferro, L., Karponi, G., Bartido, S., Giardina, P., Heller, G., Prockop, S. E., et al. (2014) · Blood · doi:10.1182/blood-2013-06-507178 · Cited by 64
Self-citationGene Therapy for Hemoglobinopathies
Chandrakasan, S., & Malik, P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.12.003 · Cited by 62
Papapetrou, E. P., Korkola, J. E., & Sadelain, M. (2010) · Stem Cells · doi:10.1002/stem.257 · Cited by 73
Self-citationBianchi, N., Chiarabelli, C., Borgatti, M., Mischiati, C., Fibach, E., & Gambari, R. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02843.x · Cited by 73
“Similarly, it could be of great interest to determine whether tallimustine is able to alter globin gene expression in the large variety of beta- and alpha-thalassaemic mice so far described (Shehee et al, 1993; Yang et al, 1995; Paszty, 1997; May et al, 2000).”
BackgroundTrobridge, G. D., Beard, B. C., Gooch, C., Wohlfahrt, M. E., Olsen, P., Fletcher, J., Malik, P., & Kiem, H. (2008) · Blood · doi:10.1182/blood-2007-09-115022 · Cited by 72
Suwanmanee, T., Sierakowska, H., Lacerra, G., Svasti, S., Kirby, S. L., Walsh, C., Fucharoen, S., & Kole, R. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.545 · Cited by 71
“Li et al., 1999; May et al., 2000), although very promising, are still not a clinical reality.”
BackgroundZhou, B. Y., Ye, Z., Chen, G., Gao, Z. P., Zhang, Y. A., & Cheng, L. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0128 · Cited by 71
Rohll, J. B., Mitrophanous, K. A., Martin‐Rendon, E., Ellard, F. M., Radcliffe, P. A., Mazarakis, N. D., & Kingsman, S. M. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)46072-7 · Cited by 70
Gene Therapy for Hemoglobinopathies
Cavazzana, M., & Mavilio, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.122 · Cited by 70
Boulad, F., Maggio, A., Wang, X., Moi, P., Acuto, S., Kogel, F., Takpradit, C., Prockop, S. E., Mansilla‐Soto, J., Cabriolu, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01554-9 · Cited by 69
Self-citationArumugam, P. I., Urbinati, F., Velu, C. S., Higashimoto, T., Grimes, H. L., & Malik, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006995 · Cited by 62
Survival of the fittest: in vivo selection and stem cell gene therapy
Neff, T., Beard, B. C., & Kiem, H. (2005) · Blood · doi:10.1182/blood-2005-06-2335 · Cited by 68
Gene therapy of apolipoprotein E–deficient mice using a novel macrophage-specific retroviral vector
Gough, P. J., & Raines, E. W. (2002) · Blood · doi:10.1182/blood-2002-07-2131 · Cited by 67
Richard, E., Méndez, M., Mazurier, F., Morel, C., Costet, P., Xia, P., Fontanellas, A., Géronimi, F., Cario, M., Taine, L., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0467 · Cited by 67
Thalassemias: from gene to therapy
Simone, G. D., Quattrocchi, A., Mancini, B., di Masi, A., Nervi, C., & Ascenzi, P. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101028 · Cited by 66
Optimal conditions for lentiviral transduction of engrafting human CD34+ cells
Uchida, N., Hsieh, M. M., Hayakawa, J., Madison, C., Washington, K. N., & Tisdale, J. F. (2011) · Gene Therapy · doi:10.1038/gt.2011.63 · Cited by 57
Overview of the HIV‐1 Lentiviral Vector System
Ramezani, A., & Hawley, R. G. (2002) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1621s60 · Cited by 46
“…and retina (Naldini et al., 1996a,b; Kafri et al., 1997; Miyoshi et al., 1997; Kordower et al., 1999) as well as undifferentiated stem cells and embryos (Hamaguchi et al., 2000; May et al., 2000; Hawley, 2001; Pawliuk et al., 2001; Wolfgang et al., 2001; Lois et al., 2002; Pfeifer et al., 2002).”
BackgroundPathophysiological-Based Approaches to Treatment of Sickle Cell Disease
Steinberg, M. H., & Brugnara, C. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152439 · Cited by 65
Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced
Leonard, A. K., & Tisdale, J. F. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1486703 · Cited by 64
Gelderman, M. P., Baek, J. H., Yalamanoglu, A., Puglia, M., Vallelian, F., Burla, B., Vostal, J., Schaer, D. J., & Buehler, P. W. (2015) · Haematologica · doi:10.3324/haematol.2014.117325 · Cited by 63
Papapetrou, E. P., Kovalovsky, D., Beloeil, L., Sant’Angelo, D., & Sadelain, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37216 · Cited by 59
Self-citationGene Delivery by Lentivirus Vectors An Overview
Kafri, T. (2004) · Gene Delivery to Mammalian Cells · doi:10.1385/1-59259-650-9:367 · Cited by 55
Benhamida, S., Pflumio, F., Dubart-Kupperschmitt, A., Zhao-Emonet, J.-C., Cavazzana-Calvo, M., Rocchiccioli, F., Fichelson, S., Aubourg, P., Charneau, P., & Cartier, N. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00002-9 · Cited by 61
Stem cells today: A. Origin and potential of embryo stem cells
Edwards, R. G. (2004) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60910-8 · Cited by 61
Transcriptional Targeting of Lentiviral Vectors by Long Terminal Repeat Enhancer Replacement
Lotti, F., Menguzzato, E., Rossi, C., Naldini, L., Ailles, L., Mavilio, F., & Ferrari, G. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.3996-4007.2002 · Cited by 61
Gene therapy for hemoglobinopathies: progress and challenges
Dong, A., Rivella, S., & Breda, L. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.011 · Cited by 60
Self-citationGene Therapy For Beta-Thalassemia: Updated Perspectives
Karponi, G., & Ζώγας, Ν. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s178546 · Cited by 60
Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies
Payen, E., & Leboulch, P. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.276.3807841 · Cited by 59
Gene Therapy Approaches to Hemoglobinopathies
Ferrari, G., Cavazzana, M., & Mavilio, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.010 · Cited by 56
Ramos, P., Guy, E., Chen, N., Proenca, C. C., Gardenghi, S., Casu, C., Follenzi, A., Van Rooijen, N., Grady, R. W., de Sousa, M., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307462 · Cited by 54
Self-citationMolete, J. M., Petrykowska, H., Bouhassira, E. E., Feng, Y.-Q., Miller, W., & Hardison, R. C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.9.2969-2980.2001 · Cited by 49
Nanoencapsulation of arsenate with nanoscale zero-valent iron (nZVI): A 3D perspective
Liu, A., Wang, W., Liu, J., Fu, R., & Zhang, W. (2018) · 中国科学通报:英文版 · doi:10.1016/j.scib.2018.12.002 · Cited by 57
Gene therapy for monogenic disorders of the bone marrow
Ghosh, S., Thrasher, A. J., & Gaspar, H. B. (2015) · British Journal of Haematology · doi:10.1111/bjh.13520 · Cited by 56
“Elements upstream of HBB, known as the locus control region (LCR), which confer high level expression of b-globin in the erythroid lineage (Tuan & London, 1984) have been used in the construction of vectors.”
BackgroundInfluentialKarponi, G., Psatha, N., Lederer, C. W., Adair, J. E., Zervou, F., Ζώγας, Ν., Kleanthous, M., Tsatalas, C., Anagnostopoulos, Α., Sadelain, M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-629618 · Cited by 56
Self-citationUchida, N., Washington, K. N., Hayakawa, J., Hsieh, M. M., Bonifacino, A. C., Krouse, A. E., Metzger, M. E., Donahue, R. E., & Tisdale, J. F. (2009) · Journal of Virology · doi:10.1128/jvi.00357-09 · Cited by 56
Vacek, M. M., Ma, H., Gemignani, F., Lacerra, G., Kafri, T., & Kole, R. (2002) · Blood · doi:10.1182/blood-2002-06-1869 · Cited by 56
Gene therapy of severe combined immunodeficiencies
Cavazzana, M., Hacein‐Bey‐Abina, S., Yates, F., de Villartay, J., Deist, F. L., & Fischer, A. (2001) · The Journal of Gene Medicine · doi:10.1002/1521-2254(200105/06)3:3<201::aid-jgm195>3.0.co;2-z · Cited by 56
Optimizing Retroviral Gene Expression for Effective Therapies
Antoniou, M. N., Skipper, K. A., & Anakök, Ö. F. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.062 · Cited by 56
“The breakthrough in the field occurred with the report of the first LV (named ‘‘TNS9’’) harboring a b LCR-HBB transcription unit (May et al ., 2000).”
InfluentialSong, L., Li, X., Jayandharan, G. R., Wang, Y., Aslanidi, G. V., Ling, C., Zhong, L., Gao, G., Yoder, M. C., Ling, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058757 · Cited by 54
Black, J., & Vos, J. M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301808 · Cited by 55
Hematopoietic stem cell engineering at a crossroads
Rivière, I., Dunbar, C. E., & Sadelain, M. (2012) · Blood · doi:10.1182/blood-2011-09-349993 · Cited by 54
Self-citationEvolution of Gene Therapy, Historical Perspective
Malech, H. L., Garabedian, E., & Hsieh, M. M. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.001 · Cited by 54
Lisowski, L., & Sadelain, M. (2007) · Blood · doi:10.1182/blood-2007-08-108647 · Cited by 54
Self-citationKim, Y.-J., Kim, Y.-S., Larochelle, A., Renaud, G., Wolfsberg, T. G., Adler, R., Donahue, R. E., Hematti, P., Hong, B.-K., Roayaei, J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-185199 · Cited by 51
Recent Advances in β-Thalassemias
Cao, A., Moi, P., & Galanello, R. (2011) · Pediatric Reports · doi:10.4081/pr.2011.e17 · Cited by 53
Taher, A. T., Bou‐Fakhredin, R., Kattamis, A., Viprakasit, V., & Cappellini, M. D. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1977116 · Cited by 53
Hematopoietic Stem Cell Transplantation for Thalassemia
Gaziev, J., & Lucarelli, G. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811795495413 · Cited by 52
Goodman, M., & Malik, P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716653729 · Cited by 52
“In the first, a lentivirus carrying DNase I hypersensitive site 2 (HS2), HS3, and HS4 of the LCR and the human β-globin gene was able to ameliorate disease in a β-thalassemia mouse model [May et al. 2000].”
BackgroundXie, S., Ren, Z., Zhang, J.-Z., Guo, X., Wang, Q., Wang, S., Lin, D., Gong, X., Li, W., Huang, S., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm218 · Cited by 52
Physiological and tissue-specific vectors for treatment of inherited diseases
Toscano, M. G., Romero, Z. G., Muñoz, P., Cobo, M., Benabdellah, K., & Martín, F. (2010) · Gene Therapy · doi:10.1038/gt.2010.138 · Cited by 51
High, K. A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01460.x · Cited by 51
Therapeutic Options for Patients with Severe β-Thalassemia: The Need for Globin Gene Therapy
Sadelain, M., Boulad, F., Galanello, R., Giardina, P. J., Locatelli, F., Maggio, A., Rivella, S., Rivière, I., & Tisdale, J. F. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.151 · Cited by 51
Self-citationSafety considerations in vector development.
Kappes, J. C., & Wu, X. (2001) · Somatic Cell and Molecular Genetics · doi:10.1023/a:1021082815013 · Cited by 50
Targeted approaches for gene therapy and the emergence of engineered meganucleases
Galetto, R., Duchateau, P., & Pâques, F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903213669 · Cited by 42
“For a decade, no artificial construct could compare with the endogenous locus in terms of expression, and therefore, provide therapeutic levels of expression [11,12].”
BackgroundRecent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia
Sadelain, M. (2006) · Current Opinion in Hematology · doi:10.1097/01.moh.0000219658.57915.d4 · Cited by 50
Self-citationGene therapy for genetic haematological disorders and immunodeficiencies
Kohn, D. B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00803.x · Cited by 42
Genetic Therapy for Beta-Thalassemia: From the Bench to the Bedside
Arumugam, P. I., & Malik, P. (2010) · Hematology · doi:10.1182/asheducation-2010.1.445 · Cited by 49
Daniel-Moreno, A., Lamsfus‐Calle, A., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0510-8 · Cited by 49
Morgan, R. A., Unti, M. J., Aleshe, B., Brown, D., Osborne, K. S., Koziol, C., Ayoub, P. G., Smith, O. B., O’Brien, R., Tam, C., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.020 · Cited by 49
Genomic Domains and Regulatory Elements Operating at the Domain Level
Razin, S. V., Farrell, C. M., & Targa, F. R. (2003) · International review of cytology · doi:10.1016/s0074-7696(03)01002-7 · Cited by 49
Stallworth, J. R., Jerrell, J. M., & Tripathi, A. (2010) · American Journal of Hematology · doi:10.1002/ajh.21772 · Cited by 49
A review of gene therapy for haematological disorders
Nathwani, A. C., Davidoff, A. M., & Linch, D. C. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05231.x · Cited by 49
“Indeed, lentiviral vectors containing complex globin expression cassettes have been successfully used to cure mouse 8 ª 2004 Blackwell Publishing Ltd, British Journal of Haematology, 128, 3–17 models of sickle cell disease and b-thalassaemia (May et al, 2000, 2002; Pawliuk et al, 2001).”
MethodHino, S., Fan, J., Taguwa, S., Akasaka, K., & Matsuoka, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302227 · Cited by 49
Nanotechnology-enabled gene delivery for cancer and other genetic diseases
Jiang, T., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2200246 · Cited by 48
Malik, P., Arumugam, P. I., Yee, J.-K., & Puthenveetil, G. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.030 · Cited by 48
FIV: from lentivirus to lentivector
Saenz, D. T., & Poeschla, E. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.500 · Cited by 48
Sabatino, D. E., Seidel, N. E., Aviles-Mendoza, G. J., Cline, A. P., Anderson, S. M., Gallagher, P. G., & Bodine, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.230453097 · Cited by 48
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
Mechanisms That Regulate Silencing of Gene Expression from Retroviral Vectors
Swindle, C. S., & Klug, C. A. (2002) · Stem Cells and Development · doi:10.1089/15258160260090915 · Cited by 47
Pharmacologically regulated cell therapy
Neff, T., & Blau, C. A. (2001) · Blood · doi:10.1182/blood.v97.9.2535 · Cited by 47
Zhao, H., Pestina, T. I., Nasimuzzaman, M., Mehta, P. K., Hargrove, P. W., & Persons, D. A. (2009) · Blood · doi:10.1182/blood-2008-10-186684 · Cited by 46
Lutzko, C., Senadheera, D., Skelton, D. C., Petersen, D., & Kohn, D. B. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7341-7351.2003 · Cited by 46
Tan, M., Qing, K., Zhou, S., Yoder, M. C., & Srivastava, A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0346 · Cited by 47
Gene Therapy for Human Severe Combined Immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., Deist, F. L., Basile, G. D. S., & Cavazzana, M. (2001) · Immunity · doi:10.1016/s1074-7613(01)00175-3 · Cited by 46
Therapeutic applications for hematopoietic stem cell gene transfer
Bordignon, C., & Roncarolo, M. G. (2002) · Nature Immunology · doi:10.1038/ni0402-318 · Cited by 46
Porter, J. B. (2018) · Hematology · doi:10.1182/asheducation-2018.1.361 · Cited by 45
Development of gene therapy for hematopoietic stem cells using lentiviral vectors
WOODS, N., Ooka, A., & Karlsson, S. (2002) · Leukemia · doi:10.1038/sj.leu.2402447 · Cited by 44
Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies
Li, C., Psatha, N., Wang, H., Singh, M., Samal, H. B., Zhang, W., Ehrhardt, A., Izsvák, Z., Papayannopoulou, T., & Lieber, A. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.004 · Cited by 44
Progress Toward the Genetic Treatment of the β‐Thalassemias
Sadelain, M., Lisowski, L., Samakoglu, S., Rivella, S., May, C., & Rivière, I. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.010 · Cited by 44
Self-citationStem Cell Therapy for Sickle Cell Disease: Transplantation and Gene Therapy
Walters, M. C. (2005) · Hematology · doi:10.1182/asheducation-2005.1.66 · Cited by 44
Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders
Persons, D. A. (2009) · Hematology · doi:10.1182/asheducation-2009.1.690 · Cited by 43
Gene therapy for the hemoglobin disorders
Persons, D. A., & Tisdale, J. F. (2004) · Seminars in Hematology · doi:10.1053/j.seminhematol.2004.07.004 · Cited by 43
Metadata
- Authors
- May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Sadelain, Michel
- Venue
- Nature
- Published
- 2000-07
- Volume
- 406
- Issue
- 6791
- Pages
- 82-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1997170085
- Cited by
- 567
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 10 · 2019: 16 · 2018: 26 · 2017: 18 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 22 · 2012: 24
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- James S. McDonnell Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- beta-thalassemia, sickle cell disease, lentiviral transduction, human beta-globin gene, hematopoietic stem cells, locus control region, hemoglobin synthesis, anemia, erythrocyte morphology, position effect, transcriptional silencing
- MeSH terms
- Animals, Cell Line, Female, Genetic Vectors, Globins, Hemoglobins, Humans, Male, Recombinant Proteins, Transduction, Genetic, Genetic Therapy, HIV-1, Bone Marrow Transplantation, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.